Skip to content Skip to footer
Subscribe Now
Top 20 immunology companies of 2025
TOP 20

Top 20 Immunology Companies of 2025

Shots:  Immunology continues to be a key focus area, with biopharmaceutical companies rigorously advancing innovative therapies including drugs, vaccines, and antibodies to address evolving patient needs and improve disease outcomes  In 2024, the global immunology market size was valued at $109.4B and expected to reach $254.23B by 2032, with a CAGR of 11.8% from 2024…
July 24, 2025

Read more

GSK New
NEWS

GSK Receives the US FDA’s Approval for Benlysta to Treat Active Lupus Nephritis (LN)

Shots: The US FDA has approved Benlysta (belimumab) 200 mg/mL Autoinjector for SC use in pts (age≥5) with active LN receiving standard therapy Benlysta (belimumab) is a BLyS-specific inhibitor that reduces B cell survival and differentiation by binding to soluble BLyS, targeting autoreactive B cells. With this approval, GSK offers a first-of-its-kind at-home SC option…
June 25, 2025

Read more

Viewpoints_Mike Crichton
VIEWPOINTS

PharmaShots Interview: GSK’s Mike Crichton Shares Insights on the Approval of Benlysta in Europe

In an interview with PharmaShots, Mike Crichton, Senior Vice President, Global Therapy Area Head, Specialty & Primary Care at GSK shares his views on the European Commission's approval of Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN). Shots: The European Commission approved the expanded use of GSK's…
June 8, 2021

Read more